Randomized trial evaluates mandibular morphology outcomes over 12 months following onabotulinumtoxinA treatment for muscle prominence, indicating no detected changes.
Quantitative and qualitative MDCT evaluations showed no detectable differences in predefined mandibular morphometric measures versus placebo after 1 or 2 onabotulinumtoxinA treatments for MMP over 1 year. Safety events were localized and consistent with drug mechanism. Late-emerging effects beyond 12 months cannot be excluded.
No takes yet. Share an insight, caveat, or question.
Mallya et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: